Advanced

Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis

Hesselstrand, Roger LU ; Nagel, Johanna LU ; Saxne, Tore LU ; Geborek, Pierre LU ; Skattum, Lillemor LU and Kapetanovic, Meliha C. LU (2018) In Rheumatology (United Kingdom) 57(4). p.625-630
Abstract

Objective. To study the impact of disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23) in patients with SSc. Methods. Forty-four SSc patients and 49 controls received a dose of either PCV13 or PPV23. Twelve patients were treated with DMARDs. Antibody levels to pneumococcal polysaccharides 6B and 23 F were measured before and 4-6 weeks after vaccination using ELISA. Antibody functionality was studied using opsonophagocytic assay performed on serotype 23 F. Results. Number of patients, percentage female and mean age (years) at vaccination were: 32, 94%, 57.5 years in SSc without DMARDs; 12, 100%, 55.5 years in SSc on DMARDs and 49,... (More)

Objective. To study the impact of disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23) in patients with SSc. Methods. Forty-four SSc patients and 49 controls received a dose of either PCV13 or PPV23. Twelve patients were treated with DMARDs. Antibody levels to pneumococcal polysaccharides 6B and 23 F were measured before and 4-6 weeks after vaccination using ELISA. Antibody functionality was studied using opsonophagocytic assay performed on serotype 23 F. Results. Number of patients, percentage female and mean age (years) at vaccination were: 32, 94%, 57.5 years in SSc without DMARDs; 12, 100%, 55.5 years in SSc on DMARDs and 49, 63% and 50.6 years in controls. Post-vaccination antibody levels for both serotypes increased significantly in SSc without DMARDs and controls (P < 0.001), but in SSc on DMARDs only for 6B (P = 0.041). Compared with the other groups, patients with SSc receiving DMARDs had lower post-vaccination antibody levels for both serotypes. Opsonophagocytic assay increased significantly in all three groups. No significant difference in immunogenicity between PCV13 and PPV23 was seen. Conclusion. Pneumococcal vaccination using either PCV13 or PPV23 yielded satisfactory antibody response in SSc patients without DMARD treatment, but a lower response in patients treated with synthetic DMARDs. Type of pneumococcal vaccine (conjugate or polysaccharide) did not significantly influence antibody response.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antibody response, Immunogenicity, Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine, Pneumococcal vaccination, Systemic sclerosis
in
Rheumatology (United Kingdom)
volume
57
issue
4
pages
6 pages
publisher
Oxford University Press
external identifiers
  • scopus:85045077781
ISSN
1462-0324
DOI
10.1093/rheumatology/kex471
language
English
LU publication?
yes
id
10db9b82-32df-4063-ac74-7b5e1f41ef81
date added to LUP
2018-04-19 14:38:54
date last changed
2019-02-20 11:14:41
@article{10db9b82-32df-4063-ac74-7b5e1f41ef81,
  abstract     = {<p>Objective. To study the impact of disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23) in patients with SSc. Methods. Forty-four SSc patients and 49 controls received a dose of either PCV13 or PPV23. Twelve patients were treated with DMARDs. Antibody levels to pneumococcal polysaccharides 6B and 23 F were measured before and 4-6 weeks after vaccination using ELISA. Antibody functionality was studied using opsonophagocytic assay performed on serotype 23 F. Results. Number of patients, percentage female and mean age (years) at vaccination were: 32, 94%, 57.5 years in SSc without DMARDs; 12, 100%, 55.5 years in SSc on DMARDs and 49, 63% and 50.6 years in controls. Post-vaccination antibody levels for both serotypes increased significantly in SSc without DMARDs and controls (P &lt; 0.001), but in SSc on DMARDs only for 6B (P = 0.041). Compared with the other groups, patients with SSc receiving DMARDs had lower post-vaccination antibody levels for both serotypes. Opsonophagocytic assay increased significantly in all three groups. No significant difference in immunogenicity between PCV13 and PPV23 was seen. Conclusion. Pneumococcal vaccination using either PCV13 or PPV23 yielded satisfactory antibody response in SSc patients without DMARD treatment, but a lower response in patients treated with synthetic DMARDs. Type of pneumococcal vaccine (conjugate or polysaccharide) did not significantly influence antibody response.</p>},
  author       = {Hesselstrand, Roger and Nagel, Johanna and Saxne, Tore and Geborek, Pierre and Skattum, Lillemor and Kapetanovic, Meliha C.},
  issn         = {1462-0324},
  keyword      = {Antibody response,Immunogenicity,Pneumococcal conjugate vaccine,Pneumococcal polysaccharide vaccine,Pneumococcal vaccination,Systemic sclerosis},
  language     = {eng},
  month        = {04},
  number       = {4},
  pages        = {625--630},
  publisher    = {Oxford University Press},
  series       = {Rheumatology (United Kingdom)},
  title        = {Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis},
  url          = {http://dx.doi.org/10.1093/rheumatology/kex471},
  volume       = {57},
  year         = {2018},
}